SI-BONE, Inc. (SIBN)
NASDAQ: SIBN · Real-Time Price · USD
12.15
-0.17 (-1.38%)
Nov 20, 2024, 4:00 PM EST - Market closed
SI-BONE Revenue
SI-BONE had revenue of $40.34M in the quarter ending September 30, 2024, with 18.60% growth. This brings the company's revenue in the last twelve months to $157.04M, up 18.98% year-over-year. In the year 2023, SI-BONE had annual revenue of $138.89M with 30.52% growth.
Revenue (ttm)
$157.04M
Revenue Growth
+18.98%
P/S Ratio
3.18
Revenue / Employee
$456,497
Employees
344
Market Cap
509.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 138.89M | 32.48M | 30.52% |
| Dec 31, 2022 | 106.41M | 16.26M | 18.03% |
| Dec 31, 2021 | 90.15M | 16.77M | 22.84% |
| Dec 31, 2020 | 73.39M | 6.09M | 9.04% |
| Dec 31, 2019 | 67.30M | 11.92M | 21.53% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Auna S.A. | 1.10B |
| Organogenesis Holdings | 455.04M |
| Silence Therapeutics | 21.77M |
| IGM Biosciences | 2.92M |
| Mereo BioPharma Group | 1.00M |
| Opthea | 261.86K |
SIBN News
- 17 hours ago - SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024 - GlobeNewsWire
- 8 days ago - SI-BONE, Inc. (SIBN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 8 days ago - SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance - GlobeNewsWire
- 16 days ago - SI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite™ - GlobeNewsWire
- 4 weeks ago - SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024 - GlobeNewsWire
- 6 weeks ago - SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation - GlobeNewsWire
- 3 months ago - SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024 - GlobeNewsWire
- 3 months ago - SI-BONE, Inc. Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System - GlobeNewsWire